Home › NDC Lookup › J-codes › J0742
J0742

J0742 – Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 1 NDC crosswalked per 4 MG-4 MG-2 MG $2.691/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J0742 summary

J0742 is a HCPCS Level II J-code used to bill imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg, billed per 4 MG-4 MG-2 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J0742: Recarbrio

Code J0742 Billing unit 4 MG-4 MG-2 MG Payment limit $2.691/unit NDC-Crosswalk 1 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ0742
DescriptorInjection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
Billing unit4 MG-4 MG-2 MG
Payment limit / unit$2.691
Est. ASP / unit$2.539 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20

💊 About Imipenem, Cilastatin, and Relebactam Injection DRUG GUIDE

Recarbrio (imipenem, cilastatin, and relebactam) is used to treat serious bacterial infections in adults and in children weighing at least 2 kg.

It targets infections caused by susceptible gram-negative bacteria — the kinds that can be resistant to many other antibiotics.Recarbrio is approved to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

It is also approved — in patients who have limited or no other treatment options — for complicated urinary tract infections (cUTI), including pyelonephritis (a kidney infection), and complicated intra-abdominal infections (cIAI) such as serious abdominal cavity infections.

Read the full Imipenem, Cilastatin, and Relebactam Injection drug guide →
Clinical overview from our editorial drug guide for Imipenem, Cilastatin, and Relebactam Injection. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.691
Est. ASP / unit
$2.539 est.
Est. after 2% sequester
$2.637
HCPCS dosage
4 MG-4 MG-2 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2020-07-01
Date added2020-07-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J0742 = 4 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J0742 WITH EST. MEDICARE PAY

1 NDC map to J0742. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.691/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00006-3856-02 RECARBRIO imipenem anhydrous, cilastatin, and relebactam anhydrous 500 mg/100mL; 500 mg/100mL; 250 mg/100mL INJECTION, POWDER, FOR SOLUTION Merck 25 VIAL, SINGLE-DOSE in 1 CARTON (0006-385... 500 mg/100mL; 500 mg/100mL; 250 mg/100mL 3,125 $8,409.38 — ● Active CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)

Total Part B spend
$8.5K
Claims
178
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$48.03
Where J0742 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #812 of 918
#807 MANNITOL(J2150) J2150 $9.3K #808 INTEGRA MATRIX** Q4108 $9.2K #809 IMMPHENTIV J2373 $9K #810 CEFAZOLIN SODIUM(J06... J0687 $9K #811 DOXY 100* J1271 $8.6K #812 RECARBRIO J0742 $8.5K #813 VARUBI J8670 $8.5K #814 LEVOFLOXACIN-D5W J1956 $8.2K #815 PREDNISOLONE SODIUM... J7510 $7.9K #816 GLYCOPYRROLATE(J1598... J1598 $7.6K #817 PREHEVBRIO 90759 $7.6K
Total claims — #735 of 918
#730 ZEMDRI J0291 202 #731 DIHYDROERGOTAMINE ME... J1110 200 #732 DIMENHYDRINATE J1240 200 #733 AVONEX (4 PACK)* Q3027 187 #734 ACTEMRA(Q0249) Q0249 183 #735 RECARBRIO J0742 178 #736 PERSERIS J2798 178 #737 ELAPRASE J1743 176 #738 CYTAL, PER SQUARE CE... Q4166 176 #739 YEZTUGO(J0738) J0738 174 #740 ERZOFRI J2428 174

Full breakdown by period (1)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2025 (Q1-Q4) $8.5K — 178 — $48.03
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$0.00
Medicare paid
$0.00
Submitted services
1,360
Denial rate
100.0%
Submitted charges
$78.1K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J0742 is utilized

⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J0742 billing FAQ

What is HCPCS code J0742?
J0742 is a HCPCS Level II J-code used to bill Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0742?
One unit of J0742 represents 4 MG-4 MG-2 MG. Report the number of units equal to the dose administered divided by 4 MG-4 MG-2 MG.
How many units of J0742 should I bill?
Divide the dose administered by the code's unit size (4 MG-4 MG-2 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0742?
The Medicare Part B payment limit is $2.691 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.637 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0742?
1 NDC currently map to J0742 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0742 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.